Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

被引：227

作者：

Goetz, Matthew P. ^{[1
]}

Sangkuhl, Katrin ^{[2
]}

Guchelaar, Henk-Jan ^{[3
]}

Schwab, Matthias ^{[4
,5
,6
]}

Province, Michael ^{[7
]}

Whirl-Carrillo, Michelle ^{[2
]}

Symmans, W. Fraser ^{[8
]}

McLeod, Howard L. ^{[9
]}

Ratain, Mark J. ^{[10
]}

Zembutsu, Hitoshi ^{[11
]}

Gaedigk, Andrea ^{[12
,13
]}

van Schaik, Ron H. ^{[14
,15
]}

Ingle, James N. ^{[1
]}

Caudle, Kelly E. ^{[16
]}

Klein, Teri E. ^{[2
]}

机构：

[1] Mayo Clin, Dept Oncol, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA

[2] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[3] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands

[4] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[5] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany

[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany

[7] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Chicago, Ctr Personalized Therapeut, Chicago, IL 60637 USA

[11] Natl Canc Ctr, Div Human Genet, Res Inst, Tokyo, Japan

[12] Univ Missouri, Div Clin Pharmacol Toxicol & Therapeut Innovat, Childrens Mercy Kansas City, Kansas City, MO 64110 USA

[13] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[14] Erasmus MC, Int Expertctr Pharmacogenet, Dept Clin Chem, Rotterdam, Netherlands

[15] LKCH UMC Utrecht, Utrecht, Netherlands

[16] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期

基金：

美国国家卫生研究院;

关键词：

BREAST-CANCER PATIENTS; ADJUVANT TAMOXIFEN; ESTROGEN-RECEPTOR; IN-VITRO; POSTMENOPAUSAL WOMEN; ACTIVE METABOLITE; CODEINE THERAPY; GENOTYPE; CYP2C19-ASTERISK-2; POLYMORPHISMS;

D O I：

10.1002/cpt.1007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

引用

页码：770 / 777

页数：8

共 50 条

[21] CYP2D6 pharmacogenetics stratifies tamoxifen treatment outcome
Schroth, W.
Goetz, M. R.
Hamann, U.
Fasching, P. A.
Schmidt, M.
Winter, S.
Fritz, P.
Suman, V. J.
Ames, M. M.
Simon, W.
Ulmer, H.
Bolaender, J.
Strick, R.
Beckmann, M. W.
Koelbl, H.
Black, J.
Avila, R.
Weinshilboum, R.
Ingle, J. N.
Eichelbaum, M.
Schwab, M.
Brauch, H.
BREAST, 2009, 18 : S34 - S34
[22] THE CLINICAL PHARMACOGENETICS IMPLEMENTATION CONSORTIUM (CPIC) CLINICAL PRACTICE GUIDELINES
Caudle, Kelly
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : 1063 - 1064
[23] Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy
Duarte, Julio D.
Thomas, Cameron D.
Lee, Craig R.
Huddart, Rachel
Agundez, Jose A. G.
Baye, Jordan F.
Gaedigk, Andrea
Klein, Teri E.
Lanfear, David E.
Monte, Andrew A.
Nagy, Mohamed
Schwab, Matthias
Stein, C. Michael
Uppugunduri, Chakradhara Rao S.
van Schaik, Ron H. N.
Donnelly, Roseann S.
Caudle, Kelly E.
Luzum, Jasmine A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 939 - 947
[24] Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Caudle, Kelly E.
Klein, Teri E.
Hoffman, James M.
Mueller, Daniel J.
Whirl-Carrillo, Michelle
Gong, Li
McDonagh, Ellen M.
Sangkuhl, Katrin
Thorn, Caroline F.
Schwab, Matthias
Agundez, Jose A. G.
Freimuth, Robert R.
Huser, Vojtech
Lee, Ming Ta Michael
Iwuchukwu, Otito F.
Crews, Kristine R.
Scott, Stuart A.
Wadelius, Mia
Swen, Jesse J.
Tyndale, Rachel F.
Stein, C. Michael
Roden, Dan
Relling, Mary V.
Williams, Marc S.
Johnson, Samuel G.
CURRENT DRUG METABOLISM, 2014, 15 (02) : 209 - 217
[25] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing
Gammal, R. S.
Court, M. H.
Haidar, C. E.
Iwuchukwu, O. F.
Gaur, A. H.
Alvarellos, M.
Guillemette, C.
Lennox, J. L.
Whirl-Carrillo, M.
Brummel, S. S.
Ratain, M. J.
Klein, T. E.
Schackman, B. R.
Caudle, K. E.
Haas, D. W.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (04) : 363 - 369
[26] CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
Relling, M. V.
Klein, T. E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (03) : 464 - 467
[27] AN UPDATE ON GUIDELINES FROM THE CLINICAL PHARMACOGENETICS IMPLEMENTATION CONSORTIUM (CPIC®)
Bishop, Jeffrey R.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S110 - S111
[28] Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
Caudle, Kelly E.
Sangkuhl, Katrin
Whirl-Carrillo, Michelle
Swen, Jesse J.
Haidar, Cyrine E.
Klein, Teri E.
Gammal, Roseann S.
Relling, Mary, V
Scott, Stuart A.
Hertz, Daniel L.
Guchelaar, Henk-Jan
Gaedigk, Andrea
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 116 - 124
[29] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype
Clancy, J. P.
Johnson, S. G.
Yee, S. W.
McDonagh, E. M.
Caudle, K. E.
Klein, T. E.
Cannavo, M.
Giacomini, K. M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (06) : 592 - 597
[30] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Amstutz, Ursula
Henricks, Linda M.
Offer, Steven M.
Barbarino, Julia
Schellens, Jan H. M.
Swen, Jesse J.
Klein, Teri E.
McLeod, Howard L.
Caudle, Kelly E.
Diasio, Robert B.
Schwab, Matthias
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) : 210 - 216

← 1 2 3 4 5 →